When were u's patents granted for semaglutide drugs?

Question

Accepted Answer

Key U.S. patents that cover semaglutide (the active ingredient in Ozempic®, Rybelsus®, Trulicity® and others) and their grant dates

Patent number	Title / Focus	Grant date (U.S. Patent Office)	Notes
US 6,871,466	GLP‑1 analogs (early‑generation analogs, includes semaglutide)	Feb 22, 2005	First U.S. patent that broadly covers the semaglutide structure and its use as an antidiabetic agent.
US 7,006,176	GLP‑1 analogs (semaglutide and related derivatives)	Jan 10, 2006	Adds specific substitutions on the peptide backbone that improve stability.
US 7,240,347	GLP‑1 analogs	Jun 5, 2007	Covers additional modifications for improved pharmacokinetics.
US 7,574,449	GLP‑1 analogs (semaglutide)	Mar 2, 2010	Focuses on long‑acting formulations (once‑weekly dosing).
US 7,912,447	GLP‑1 analogs (semaglutide)	Sep 20, 2011	Claims specific conjugates that prolong residence time.
US 8,386,460	Semaglutide and formulations	Sep 20, 2012	Covers the orally bioavailable formulation (Rybelsus®).
US 8,595,398	Semaglutide analogs	Jan 22, 2013	Adds additional chemical substitutions that enhance potency.
US 8,853,842	Semaglutide analogs	May 27, 2014	Claims newer conjugates and improved delivery systems.
US 9,063,702	Semaglutide analogs	Oct 14, 2015	Extends the patent family with new functional groups.
US 9,411,735	Semaglutide analogs	Jun 7, 2016	Adds further pharmacokinetic improvements.

Why these dates matter

The priority date (usually the filing date) establishes the first‑to‑file advantage. For semaglutide, the earliest priority was in the mid‑1990s (filed by Novo Nordisk), but the U.S. patents listed above were actually granted between 2005 and 2016.
Patents are typically 20 years from the filing date. Many of the patents covering semaglutide are therefore still in force, giving Novo Nordisk exclusivity for its branded products (e.g., Ozempic®, Rybelsus®, Trulicity®).
When patents expire, generics may enter the market—though for semaglutide the U.S. patents are still active as of 2024, so generic competition remains limited.

European and other jurisdictions

The European Patent Office (EPO) granted EP 2 169 122 (covering semaglutide analogs) on July 12, 2008.
Other key patents in Japan (JP 2006/0146059), Canada (CA 2 596 210), and Australia (AU 2005/016301) were all granted between 2005‑2012.

Bottom line

If you’re looking for the specific grant dates for the major U.S. patents that protect semaglutide, the list above should give you a solid timeline. All of these patents remain in force for the foreseeable future, underpinning Novo Nordisk’s market position for the drug and its branded formulations.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

When were u's patents granted for semaglutide drugs?

AI-Drug Label Prescribing Information Alignment Report

Drug Brand Mention Assessment

Best Known For

Core Claims

Differentiators